Currently, the NET versus NEC treatment options for such borderline cases are dictated by a combination of other features such as response to prior therapy, extent of disease, rate of progression based on serial radiologic studies, Ki-67 proliferation index, and mutational profile. Here, MKI67 is linked to neuroendocrine carcinoma.